Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Tyra Biosciences, Inc.
NASDAQ:TYRAHealthcare · Biotechnology
-1.91%$21.07
AH$21.07+0.00%vs close
Mkt Cap$1.45B
Float35.89M
O/S68.76M
Vol
$ Vol
RVOL
Inst Own100.9%
SI26.5%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$119.95M
Total Assets$282.61M
Free Cash Flow-$95.28M
Debt & Equity
Debt 2%
Equity 98%
Total Debt$5.81M
Total Equity$259.18M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in TYRA's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$282.61M
Liabilities$23.43M
Accounts Receivable$0
Accounts Payable$1.18M
Inventory$0
PP&E (Net)$6.89M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $47K | $8K |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | -$47K | -$8K |
| Gross Margin | - | - | - | - | - | - | - |
| Research and Development | $102.93M | $80.08M | $62.52M | $43.01M | $20.64M | $7.2M | $1.79M |
| Selling, General, and Administrative | $29.83M | $24.1M | $17.43M | $15.92M | $5.65M | $2.09M | $1.33M |
| Other | $0 | $0 | $0 | $0 | $0 | -$23K | -$8K |
| Total Operating Expenses | $132.76M | $104.18M | $79.94M | $58.93M | $26.29M | $9.25M | $3.12M |
| Operating Income (EBIT) | -$132.76M | -$104.18M | -$79.94M | -$58.93M | -$26.29M | -$9.3M | -$3.12M |
| Operating Margin | - | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1K | $1K |
| Interest Income | $12.81M | $17.7M | $10.81M | $3.65M | $13K | $0 | $0 |
| Other Income (Expense) | $12.81M | $17.7M | $10.81M | $3.6M | -$6K | -$39K | -$943K |
| Income Before Tax (EBT) | -$119.95M | -$86.48M | -$69.13M | -$55.33M | -$26.29M | -$9.34M | -$4.07M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$119.95M | -$86.48M | -$69.13M | -$55.33M | -$26.29M | -$9.31M | -$4.06M |
| Net Income Margin | - | - | - | - | - | - | - |
| Supplementary Data | |||||||
| EPS | -2.01 | -1.51 | -1.62 | -1.23 | -0.63 | -0.22 | -0.10 |
| Diluted EPS | -2.01 | -1.51 | -1.62 | -1.23 | -0.63 | -0.22 | -0.10 |
| Weighted Average OS | 59.60M | 57.22M | 42.70M | 41.88M | 41.44M | 42.54M | 42.54M |
| EBITDA | -$119.4M | -$85.96M | -$68.78M | -$55.03M | -$26.15M | -$9.25M | -$3.11M |
| EBITDA Margin | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $77.39M | $91.97M | $58.01M | $251.21M | $302.18M | $15.22M | $108K |
| Short-Term Investments | $178.62M | $249.47M | $145.46M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $256M | $341.44M | $203.47M | $251.21M | $302.18M | $15.22M | $108K |
| Accounts Receivable | $0 | $2M | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $9.45M | $4.02M | $8.2M | $6.08M | $0 | $0 | $0 |
| Total Current Assets | $265.45M | $347.46M | $211.67M | $257.29M | $304.06M | $15.28M | $127K |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $6.89M | $7.72M | $8.15M | $3.54M | $2.09M | $466K | $276K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $243K | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $10.27M | $8.38M | $6.03M | $5.35M | $555K | $21K | $125K |
| Total Long-Term Assets | $17.16M | $16.09M | $14.19M | $8.89M | $2.64M | $730K | $401K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $282.61M | $363.56M | $225.86M | $266.18M | $306.7M | $16.01M | $528K |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $1.18M | $590K | $4.66M | $1.15M | $599K | $664K | $327K |
| Short-Term Debt | $472K | $412K | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $10.91M | $7.14M | $5.27M | $0 | $0 | $278K | $4.33M |
| Total Current Liabilities | $18.09M | $14.59M | $15.33M | $5.7M | $3.62M | $1.86M | $5.16M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $5.34M | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $3K | $46K | $169K | $367K | $27.79M | $0 |
| Total Long-Term Liabilities | $5.34M | $5.81M | $6.26M | $2.65M | $1.35M | $27.79M | $114K |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $23.43M | $20.41M | $21.59M | $8.35M | $4.96M | $29.65M | $5.27M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $5K | $5K | $4K | $4K | $4K | $0 | $0 |
| Retained Earnings | -$371.26M | -$251.31M | -$164.83M | -$95.7M | -$40.37M | -$14.08M | -$4.74M |
| Comprehensive Income & Other | $393K | $770K | $381K | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $630.43M | $594.46M | $369.09M | $353.52M | $342.1M | $439K | $0 |
| Total Equity | $259.18M | $343.15M | $204.26M | $257.83M | $301.74M | -$13.64M | -$4.74M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $282.61M | $363.56M | $225.86M | $266.18M | $306.7M | $16.01M | $528K |
| Supplementary Data | |||||||
| Total Debt | $5.81M | $6.22M | $6.5M | $2.62M | $1.18M | $142K | $253K |
| Net Debt | -$71.58M | -$85.74M | -$51.51M | -$248.59M | -$301M | -$15.08M | $145K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$119.95M | -$86.48M | -$69.13M | -$55.33M | -$26.29M | -$9.34M | -$4.07M |
| Depreciation & Amortization | $546K | $519K | $357K | $296K | $140K | $47K | $8K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $28.01M | $22.8M | $13.53M | $10.59M | $2.89M | $439K | $0 |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $0 | $0 | $0 | $0 | $1.49M | $1.02M | $461K |
| Other Working Capital | -$1.63M | -$729K | $6.36M | -$5.85M | -$1.97M | $51K | $44K |
| Total Working Capital Change | -$1.63M | -$729K | $6.36M | -$5.85M | -$481K | $1.07M | $505K |
| Other Non-Cash Items | -$2.12M | -$5.88M | -$1.25M | $3K | $3K | $17K | $934K |
| Net Cash from Operating | -$95.14M | -$69.77M | -$50.14M | -$50.28M | -$23.75M | -$7.76M | -$2.62M |
| Investing Activities | |||||||
| Capital Expenditures | -$141K | -$664K | -$770K | -$559K | -$661K | -$312K | -$20K |
| Acquisitions | $0 | $0 | $0 | $0 | $16K | $0 | $0 |
| Purchases of Investments | -$101.25M | -$263.62M | -$143.84M | $0 | $0 | $0 | $0 |
| Sales of Investments | $173.86M | $165.88M | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $16 | $0 | $0 |
| Net Cash from Investing | $72.46M | -$98.4M | -$144.6M | -$559K | -$645K | -$312K | -$20K |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | $9K | $17K | $8K |
| Common Stock Issuance | $8.1M | $200M | $1.54M | $632K | $181.22M | $0 | $0 |
| Common Stock Repurchases | $0 | -$420K | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $2.56M | $0 | $0 | $514K | $140K | $165K |
| Net Cash from Financing | $8.1M | $202.14M | $1.54M | $632K | $311.35M | $23.43M | $157K |
| Forex Effect | $0 | $0 | $0 | -$757K | $0 | $0 | $0 |
| Net Change in Cash | -$14.58M | $33.96M | -$193.21M | -$50.97M | $286.96M | $15.36M | -$2.48M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$95.14M | -$69.77M | -$50.14M | -$50.28M | -$23.75M | -$7.76M | -$2.62M |
| Capital Expenditure | -$141K | -$664K | -$770K | -$559K | -$661K | -$312K | -$20K |
| Free Cash Flow | -$95.28M | -$70.44M | -$50.91M | -$50.84M | -$24.41M | -$8.07M | -$2.64M |
| Cash at Beginning | $92.97M | $59.01M | $251.21M | $302.18M | $15.47M | $108K | $2.59M |
| Cash at End | $78.39M | $92.97M | $58.01M | $251.21M | $302.43M | $15.47M | $108K |